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Abstract 
Background: We do not know how primary care treatment of depression varies by age across both 
psychotropic medication and psychological therapies.  
Methods:  Cohort study including 19,710 people aged 55+ with GP recorded depression diagnoses 
and 26,276 people with recorded depression symptoms during the period 2009-2013, from 373 
General Practices in The Health Improvement Network (THIN) database in England. 
Main outcomes were initiation of treatment with anti-depressants, anxiolytics, hypnotics, anti-
psychotic drugs, referrals to psychological therapies within six months of onset. 
Results:  Treatment rates with antidepressants are high for those recorded with new depression 
diagnoses (87.1%) or symptoms of depression (58.7%). Treatment in those with depression 
diagnoses varies little by age.  In those with depressive symptoms there was a j-shaped pattern with 
reduced antidepressant treatment in those in their 60s and 70s followed by increased treatment in 
the oldest age groups (85+years), compared to those aged 55-59 years.  Other psychotropic drug 
prescribing (hypnotics/anxiolytics, antipsychotics) all increase with increasing age. Recorded 
referrals for psychological therapies were low, and decreased steadily with increasing age, such that 
women aged 75-79 years with depression diagnoses had around six times lower odds of referral (OR 
0.17, 95%CI 0.1 to 0.29) than those aged 55-59 years, and men aged 80-84 years had around seven 
times lower (OR 0.14, 95%CI 0.05 to 0.36). 
Conclusions:  The oldest age groups with new depression diagnoses and symptoms have fewer 
recorded referrals to psychological therapies, and higher psychotropic drug treatment rates in 
primary care. This suggests potential inequalities in access to psychological therapies.  
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Introduction  
Depression is common in later life (Luppa et al., 2010), is a major public health problem and one of 
the leading causes of disease burden worldwide (Whiteford et al., 2013). Prevalence rates in people 
aged 75 years and over range from 4.6% to 9.3% for major depression defined using the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IIR or DSM-IV), and from 4.5% to 37.4% with a 
broader definition of depressive disorders using case definitions on depression symptom scales (Luppa 
et al., 2010). Depressive symptoms, with or without major depressive disorder, impair functional 
ability and wellbeing as much as the most common chronic medical conditions such as diabetes, 
chronic lung disease and heart disease (Whiteford et al., 2013). Late-life depression is associated with 
increased morbidity and all-cause mortality (Jeong et al., 2013; Diniz et al. 2013; White et al. 2015) 
and similarly sub-clinical symptoms of depression have been associated with increased morbidity and 
mortality (White et al. 2015). This increased risk of mortality with depression in later life is largely 
explained by differences in physical activity, long-term conditions and impairments in physical and 
cognitive functioning (White et al. 2015). 
 
There is evidence that late-life depression can be effectively treated with anti-depressants (Nelson et 
al. 2008; Kok et al. 2012; Thorlund et al. 2015) and psychological therapies such as Cognitive 
Behavioural Therapy (CBT) and Problem Solving Therapy (PST) (Gould et al., 2012; Cuijpers et al., 
2014).  Guidelines also suggest that GPs can consider (alongside other options) augmentation with 
antipsychotics when depression has not responded to initial anti-depressant treatment (National 
Institute for Health and Care Excellence (NICE), 2009). Hypnotics/benzodiazepines are not however 
recommended for treatment augmentation in depression (NICE, 2009). In Randomised Controlled 
Trials (RCTs) of treatment with anti-depressants in older people, there was significantly higher odds 
of improvement with anti-depressants compared to placebo (OR 1.78; 95% CI 1.42–2.24) with 
Numbers Needed to Treat (NNT) of 6.7 (95%CI 4.8-10), and no significant differences between type of 
anti-depressant (Kok et al; 2012).  In RCTs of psychological therapies compared to treatment as usual 
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in older people there are also significant improvement in symptoms for both CBT (14 trials, effect size 
-0.57; 95%CI -0.80 to -0.34) (Gould et al.., 2012) and PST (3 trials, effect size 0.46; 95%CI 0.18-0.74) 
(Cuijpers et al., 2014).  Combining all psychotherapies compared to treatment as usual in 44 trials, the 
effect size is 0.64 (95%CI 0.47-0.80), corresponding to a NNT of 3. 
 
However evidence from the United Kingdom (UK) has suggested older people are less likely to attend 
psychological therapies (Royal College of Psychiatrists, 2013; de Lusignan et al., 2012) and limited 
older evidence, mainly from North America, suggests they may be less likely to be treated in any 
modality (Unützer et al., 2000; Crystal et al., 2003; Harman et al., 2004; Kessler et al., 2005). It is not 
known if there are additional inequalities in treatment in older people living in more deprived or more 
rural areas, although there is some evidence that poorer older people may receive less treatment, in 
particular less psychotherapy (Crystal et al., 2003). A greater understanding of the variation in 
treatment patterns for depression in primary care by age is required to identify whether there is 
evidence of inequitable access to care in contemporary practice. We have investigated the variation 
by age, gender, deprivation and neighbourhood in recorded primary care treatment for depression 
and symptoms of depression in older adults in England. 
 
Methods 
Study design: Population-based longitudinal cohort study. 
 
Data source:  We used data from The Health Improvement Network (THIN) UK primary care database 
(http://www.csdmruk.imshealth.com/), which contains the medical records of nearly 12 million 
patients from across the UK. This database is broadly representative of the UK population (Blak et al., 
2011) and includes information on consultations, symptoms, diagnoses, investigations, health 
measurements, demographics, prescriptions, surgical procedures and referrals. Information on 
medical conditions is entered using Read Codes (Booth, 1994), a hierarchical coding system including 
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diagnoses (which map into ICD-10 codes) and symptom codes.  THIN data are linked to UK Census data 
using the individuals postal (zip) code, which provides measures of area deprivation, and the type of 
neighbourhood for example urban or rural. We restricted our sample to 373 practices from England, 
where we had available information on their linked Index of Multiple Deprivation (IMD) score 
(Department for Communities and Local Government, 2010) and where standard data quality criteria 
had been met (Horsfall et al., 2013).  THIN has been used extensively in epidemiological research, 
including depression (Rait et al., 2009; Harris et al., 2012) and the recorded prevalence of depression 
is broadly in line with large epidemiological studies of attendees to General Practice in Europe (King 
et al., 2008). In the UK, General Practitioners are responsible for drug prescriptions issued in the 
community within the National Health Service (NHS), so information on anti-depressant and other 
psychotropic drug use is well recorded (Centre HaSCI, 2012). 
 
Study population: We included all patients aged 55 years or older who were permanently registered 
for at least 18 months with a participating practice between 01/01/2009 and 31/12/2013, and had at 
least one diagnosis of depression or depression symptoms recorded in their GP medical record 
between 01/01/2009 and 30/06/2013. We extracted two cohorts, one with new depression 
diagnoses, and one with new depression symptoms. These were not mutually exclusive, as multiple 
episodes of depression diagnoses or symptoms were possible in the same individual, as long as they 
met criteria for separate episodes specified below. 
 
The start of the follow-up was the latest of the following: 1st January 2009, 6 months after the patient’s 
date of registration with the practice, the patient’s 55th birthday and the date the practice achieved 
an acceptable level of data quality (Horsfall et al., 2013). The end of the follow-up was the earliest of 
31st  December 2013, the patient’s date of death, the patient’s transfer out of the practice or the last 
date the practice contributed data to THIN. The records for the six months immediately following a 
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new registration with a GP were excluded to avoid pre-existing prevalent cases appearing to be new 
episodes of diagnosed depression or depressive symptoms (Lewis et al., 2005). 
 
Depression diagnoses & symptoms of depression definitions:  GPs record depression in different ways, 
using both diagnostic codes and symptom codes (e.g. “low mood”) and these coding practices have 
changed over time (Rait et al., 2009).  Thus we included both groups in these analyses. Code lists were 
created for a) depression diagnoses and b) depression symptoms using standard methods (Davé & 
Petersen, 2009) and approved by a general practitioner and psychiatrist. Entries for depression 
symptoms were identified using Read codes related to depression but are too vague or uncertain to 
be classed as diagnoses, such as “low mood” or “C/O – feeling depressed”.  As depression is often a 
recurrent disorder occurring over a lifetime we allowed patients to have multiple episodes of 
depression during follow-up.  We defined a ‘new episode’ of depression diagnoses or symptoms as 
one where in the prior 12 months (“washout” period) the patient was not prescribed any anti-
depressant drug nor had any entry in the database for symptoms or diagnoses of depression.  
 
Study variables:  
Outcomes:  We determined the initiation of treatment recorded in GP records within 6 months from 
the onset of a new episode of diagnosed depression or depression symptoms in terms of:  
i. anti-depressant drugs 
ii. hypnotics and anxiolytics drugs 
iii. anti-psychotics drugs  
iv. referrals to psychological therapies including counselling 
Records for drug treatment prescriptions were extracted using the British National Formulary (BNF) 
codes (Joint Formulary Committee, 2013). Prescriptions of amitriptyline for less than 50 mg per day 
were excluded as low doses of this drug are usually indicated for chronic pain rather than for treating 
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depression. Anti-depressant drugs include Tricyclic and related anti-depressants, Monoamine-oxidase 
inhibitors, Selective Serotonin Reuptake Inhibitors and other anti-depressant drugs. Hypnotics and 
anxiolytics include benzodiazepines, ‘z-drugs’ (zaleplon, zolpidem, zopiclone), clomethiazole, 
melatonin and buspirone. Anti-psychotics include both first and second generation oral anti-
psychotics. Further details are reported in the BNF (Joint Formulary Committee, 2013). 
 
Explanatory Variables: We estimated the effect of gender, age at onset of new episode of 
depression/symptoms, socio-economic status and type of neighbourhood on the treatment 
outcomes.  
Age was initially treated as a continuous variable and handled via restricted cubic splines (Durrleman 
& Simon, 1989). Based on our preliminary exploratory analysis, and to facilitate practical 
interpretation, we then categorised age into  8 groups: 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85-
89 and 90+ years. 
Socio-economic status was defined using the Index of Multiple Deprivation (2010), a measure at the 
small area level including 38 separate indicators accounting for 7 types of deprivation ‒ income, 
employment, health, education, barriers to housing and services, living environment and crime, 
classified into quintiles. Type of neighbourhood was measured at the small area level using the 
postcode linked to the Office of National Statistics (ONS) classification of areas in the UK population 
census, grouped into 3 categories: urban, town/fringe and rural (village, hamlet or isolated dwelling).  
 
Analyses 
We focussed on patients who had at least one new episode of diagnosed depression or depressive 
symptoms during the follow-up. For each of the new episodes we then determined whether or not 
treatment was initiated within six months from the onset. Since the data were clustered (multiple 
episodes are nested within patients, who in turn are clustered within practices), we used a generalized 
estimating equations approach with a logistic link function and a working independence correlation 
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structure (Zeger et al., 1988). This consists of fitting logistic models as if the observations were 
independent but then accounting for the lack of independence by using a robust sandwich estimator 
for the standard errors (Huber, 1967; Royall, 1986). 
 
All the models were adjusted for gender, age, deprivation quintile and type of neighbourhood. Since 
for a few of the treatment outcomes we observed significant interactions between gender and some 
of the other covariates, we stratified our analysis by gender. No important interactions between age 
groups and deprivation were found.  Some patients, especially the older and frailer ones, did not 
survive or were not in the study long enough to be started on treatment. Patients who died within six 
months from episode onset without starting treatment were included in the analysis as not receiving 
the treatment. For patients who left the study alive (e.g. by moving GP practice) within six months 
from episode onset without starting treatment we carried out extensive sensitivity analyses to 
evaluate the robustness of our results to this type of loss to follow-up. In particular, we evaluated how 
our inferential conclusions were affected under alternative hypothetical scenarios, such as assuming 
that the treatment was always initiated (best case scenario) or never initiated (worst case scenario) 
when a patient had missing information on treatment initiation.  Analysis was conducted using Stata 
version 13.  Given multiple comparisons and the increased chance of a type I error, one should be 
cautious regarding interpretations of p-values between 0.01 to 0.05. 
 
Results 
Sample characteristics  
There were 20,225 recorded new episodes of depression diagnoses in 19,710 registered patients 
aged 55 years and over within the period 01/01/2009 to 30/06/2013. There were 27,396 recorded 
new episodes of depressive symptoms  from 26,276 patients in the same period.  Just under two 
thirds of the study population were women, the median age at first episode was 64-69 years 
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(depending on diagnosis and gender) and the majority lived in urban neighbourhoods (Table 1). For 
most episodes of depression diagnoses (95.9%) and depression symptoms (93.9%) there was a 
complete six months follow-up.  
Table 1: Characteristics of the study population with diagnoses and symptoms of depression 
  Depression diagnosis   Depression symptoms 
 males females  males females 
      
No. of patients (%) 7539 (38.2%) 12171 (61.8%)  9642 (36.7%) 16634 (63.3%) 
      
Age at 1st recorded 
episode      
     
     Median  64.1 65.7  66.8 68.9 
     IQR [59.0,73.5] [59.4,75.0]  [60.2,77.0] [61.0,79.2] 
      
Area deprivation (IMD)      
1 = Least deprived 1691 (22.4%) 2670 (21.9%)  2262 (23.5%) 3856 (23.2%) 
2 1735 (23.0%) 2866 (23.6%)  2245 (23.3%) 3842 (23.1%) 
3 1590 (21.1%) 2582 (21.2%)  1973 (20.5%) 3406 (20.5%) 
4 1398 (18.5%) 2390 (19.6%)  1764 (18.3%) 3220 (19.4%) 
5= Most deprived 985 (13.1%) 1442 (11.9%)  1248 (12.9%) 2046 (12.3%) 
Missing 140 (1.9%) 221 (1.8%)  150 (1.6%) 264 (1.6%) 
      
Type of neighbourhood      
    Urban 5844 (77.5%) 9,394 (77.2%)  7269 (75.4%) 12590 (75.7%) 
    Town and fringe 910 (12.1%) 1,531 (12.6%)  1375 (14.3%) 2356 (14.2%) 
    Village, hamlet or  
    isolated dwelling 
616 (8.2%) 969 (7.9%)  807 (8.4%) 1337 (8.0%) 
    Missing 169 (2.2%) 277 (2.3%)  191 (2%) 351 (2.1%) 
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The majority of the study population only had a single episode of diagnosed depression (97.4%) or 
depression symptoms (95.9%) recorded during the study period. A few (2.6%) had two recorded 
episodes and six individuals had three episodes of diagnosed depression.  Similarly 4.0% had two 
recorded episodes of depression symptoms and 31 individuals had three episodes of depression 
symptoms.  
Treatment initiation (all ages) 
Anti-depressants were the most common treatment initiated in the six months following a newly 
recorded episode of depression or depression symptoms. For each new recorded episode of 
depression in GP records, the majority (87.1%) were treated with an anti-depressant within six 
months (Supplementary Table 1), and the majority of these (89.8%) were initiated on the same day 
as the diagnosis was first recorded. For each new recorded episode of symptoms of depression in GP 
records, more than half (58.7%) were treated with an anti-depressant within six months, and the 
majority of these (77.4%) were initiated on the same day as the symptom was first recorded.  All 
other treatment modalities were much less common. For those with a new recorded diagnosis of 
depression 14.2% were initiated on an hypnotic drug, 9.2% on an anxiolytic, and 2.7% on an anti-
psychotic drug.  Similarly for newly recorded symptoms of depression 13.4% were initiated on a 
hypnotic, 8.4% on an anxiolytic, and 2.7% on an anti-psychotic drug. For both diagnosis and 
symptoms of depression, anxiolytics and antipsychotics were initiated more often between one to 
six months after the first episode.  With overall high prescribing of antidepressants, co-prescribing 
rates were very high, such that for depression diagnoses 90.6% of people prescribed hypnotics and 
anxiolytics were also prescribed an anti-depressant, and 87.2% of these prescribed anti-psychotics 
were also prescribed an anti-depressant. For symptoms 68.5% of those prescribed hypnotics and 
anxiolytics and 68.4% of those prescribed an anti-psychotic were also prescribed an anti-depressant. 
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Recorded referrals to psychological therapies including counselling were low; only 3.5% of new 
episodes of depression diagnoses and 3.4% new episodes of depression symptoms had a code 
indicating a referral had been made within six months of presentation (Supplementary table 1).   
 
Variation in treatment by age, gender, deprivation and type of neighbourhood 
 
Depression diagnoses 
Pharmacological treatments 
Among patients with a diagnosis of depression there were no significant differences in the odds of 
being prescribed an anti-depressant by age group (Table 2). Similarly there were no differences in 
prescribing in older people by area deprivation, or by neighbourhood for men. There were some 
differences in anti-depressant prescribing by neighbourhood for women, with an increase in anti-
depressant prescribing in women living in town and fringe (suburban areas in outskirts of cities) 
neighbourhoods (OR 1.32, 95%CI 1.01 to 1.74) in comparison to those living in urban neighbourhoods.  
 
There was no significant difference by age in anxiolytic and hypnotic prescribing for men, however for 
women prescribing increased with increasing age, with the highest prescribing at age 85-89 (OR 1.61, 
95%CI 1.29 to 2.02). There were no differences in anxiolytic or hypnotic prescribing by deprivation or 
neighbourhood. Anti-psychotic prescribing in people with depression increased with age for both men 
and women, particularly in the oldest age group aged 90 and over, in both men (OR 4.09, 95%CI 1.85 
to 9.05) and women (OR 7.14, 95%CI 3.83 to 13.30) in comparison to those aged 55-59 years (Table 
3). There were no differences in anti-psychotic prescribing by either deprivation or type of 
neighbourhood. 
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Table 2: Odds ratios of drug treatment for recorded new episodes of depression diagnoses in men and women by age, deprivation and neighbourhood 
  
  
Anti-depressant prescription Anxiolytic or hypnotic prescription 
Men Women Men Women 
OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* 
 
Age group 
55-59 years 
60-64 years 
65-69 years 
70-74 years 
75-79 years 
80-84 years 
85-89 years 
90+ years 
 
 
 
1 
0.88 (0.74, 1.05) 
0.93 (0.74, 1.18) 
0.86 (0.69, 1.07) 
1.02 (0.79, 1.33) 
0.89 (0.66, 1.22) 
0.90 (0.61, 1.31) 
1.64 (0.78, 3.44) 
 
0.53 
 
 
 
 
 
 
 
 
 
 
1 
1.12 (0.95, 1.32) 
1.20 (1.00, 1.43) 
0.99 (0.81, 1.21) 
0.97 (0.79, 1.18) 
1.01 (0.80, 1.27) 
1.08 (0.79, 1.47) 
0.89 (0.60, 1.31) 
 
0.41 
 
 
 
 
 
 
 
 
 
 
1 
1.00 (0.87, 1.16) 
1.05 (0.88, 1.26) 
1.28 (1.05, 1.55) 
1.13 (0.91, 1.41) 
1.14 (0.91, 1.43) 
1.02 (0.74, 1.39) 
1.16 (0.70, 1.91) 
 
0.29 
 
 
 
 
 
 
 
 
 
1 
1.22 (1.07, 1.39) 
1.30 (1.12, 1.5) 
1.40 (1.22, 1.62) 
1.26 (1.08, 1.47) 
1.38 (1.14, 1.68) 
1.61 (1.29, 2.02) 
1.49 (1.09, 2.05) 
 
<0.001 
 
 
 
 
 
 
 
 
Deprivation 
1 (lowest) 
2 
3 
4 
5 (highest) 
 
 
1 
0.89 (0.70, 1.13) 
0.91 (0.71, 1.17) 
0.93 (0.72, 1.19) 
0.93 (0.68, 1.25) 
 
0.91 
 
 
1 
0.85 (0.69, 1.04) 
0.84 (0.67, 1.05) 
0.89 (0.72, 1.12) 
0.86 (0.63, 1.18) 
 
0.56 
 
 
1 
1.02 (0.86, 1.21) 
1.04 (0.88, 1.24) 
0.9 (0.73, 1.09) 
0.82 (0.66, 1.02) 
 
0.14 
 
 
1 
0.93 (0.81, 1.08) 
0.91 (0.78, 1.07) 
0.86 (0.72, 1.02) 
0.79 (0.66, 0.96) 
 
0.18 
 
Neighbourhood 
Urban 
Town and fringe 
Village, hamlet, 
isolated dwelling 
 
 
1 
1.01 (0.74, 1.37) 
0.95 (0.72, 1.27) 
 
0.92 
 
 
1 
1.32 (1.01, 1.74) 
0.98 (0.72, 1.33) 
 
0.02 
 
 
1 
1.23 (1.01, 1.49) 
1.10 (0.85, 1.41) 
 
0.13 
 
 
1 
1.19 (1, 1.43) 
1.10 (0.92, 1.31) 
 
0.15 
 
* From Wald test for heterogeneity 
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Table 3: Odds ratios of drug treatment and referrals for recorded new episodes of depression diagnoses in men and women by age, deprivation and neighbourhood 
  
  
Antipsychotic prescription Referral for psychological therapies 
Men Women Men Women 
OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* 
 
Age group 
55-59 years 
60-64 years 
65-69 years 
70-74 years 
75-79 years 
80-84 years 
85-89 years 
90+ years 
 
 
 
1 
0.94 (0.61, 1.45) 
1.97 (1.29, 3.00) 
1.42 (0.83, 2.44) 
1.95 (1.25, 3.03) 
2.08 (1.19, 3.63) 
1.31 (0.61, 2.82) 
4.09 (1.85, 9.05) 
 
<0.001 
 
 
 
 
 
 
 
 
 
1 
1.43 (0.90, 2.27) 
1.68 (1.00, 2.85) 
2.12 (1.35, 3.34) 
2.43 (1.56, 3.78) 
2.33 (1.40, 3.88) 
4.65 (2.98, 7.26) 
7.14 (3.83, 13.3) 
 
<0.001 
 
 
 
 
 
 
 
 
 
1 
0.69 (0.52, 0.91) 
0.53 (0.36, 0.79) 
0.41 (0.27, 0.63) 
0.43 (0.26, 0.72) 
0.14 (0.05, 0.36) 
0.24 (0.09, 0.65) 
a 
 
<0.001 
 
 
 
 
 
 
 
 
1 
0.71 (0.55, 0.92) 
0.58 (0.43, 0.78) 
0.45 (0.3, 0.67) 
0.17 (0.1, 0.29) 
0.19 (0.1, 0.36) 
0.34 (0.19, 0.62) 
0.16 (0.04, 0.63) 
 
<0.001 
 
 
 
 
 
 
 
Deprivation 
1 (lowest) 
2 
3 
4 
5 (highest) 
 
 
1 
1.04 (0.69, 1.56) 
1.13 (0.74, 1.73) 
1.28 (0.83, 1.96) 
0.93 (0.56, 1.54) 
 
0.71 
 
 
1 
1.10 (0.78, 1.55) 
1.24 (0.86, 1.77) 
0.86 (0.58, 1.27) 
1.14 (0.76, 1.70) 
 
0.43 
 
 
1 
1.03 (0.72, 1.47) 
0.78 (0.53, 1.16) 
1.03 (0.67, 1.58) 
0.84 (0.53, 1.34) 
 
0.44 
 
 
1 
0.93 (0.64, 1.36) 
0.74 (0.47, 1.15) 
0.97 (0.63, 1.48) 
1.01 (0.64, 1.60) 
 
0.46 
 
Neighbourhood 
Urban 
Town and fringe 
Village, hamlet, 
isolated dwelling 
 
 
1 
1.22 (0.77, 1.92) 
1.18 (0.68, 2.07) 
 
 
0.67 
 
 
1 
1.01 (0.69, 1.47) 
0.99 (0.65, 1.50) 
 
0.998 
 
 
1 
1.42 (0.85, 2.38) 
1.22 (0.74, 2.01) 
 
0.39 
 
 
1 
1.39 (0.84, 2.28) 
0.93 (0.56, 1.54) 
 
0.27 
* From Wald test for heterogeneity 
 
a The regression coefficient could not be estimated. 
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Non-pharmacological treatments 
The odds of recorded referral for psychological therapies including counselling reduced steadily with increasing age 
for both men and women (see Table 3). For example women aged 75-79 years were around six times less likely (OR 
0.17, 95%CI 0.1 to 0.29) to be referred than those aged 55-59 years, and men aged 80-84 years were around seven 
times less likely (OR 0.14, 95%CI 0.05 to 0.36) to be referred than men aged 55-59 years. There was no differences in 
recorded referrals for psychological therapies by either deprivation or type of neighbourhood.  
 
Depression symptoms 
Pharmacological treatments 
There was a J-shaped pattern for prescribing of anti-depressants for older people with new recording of depression 
symptoms by age group, with a reduction in prescribing for those in their 60s and 70s followed by an increase in those 
over 85 years (see Table 4). There were no significant differences in prescribing of anti-depressants by deprivation or 
type of neighbourhood.  
 
Anxiolytic and hypnotic prescribing increased with increasing age (Table 4) . There was a significant difference in 
prescribing of anxiolytics and hypnotics by deprivation for women but not men, with lower rates of prescribing for 
women living in the most deprived neighbourhoods (OR 0.80, 95%CI 0.67 to 0.96). There were significant increases in 
prescribing of anti-psychotics with increasing age, rising to a more than three-fold increase in prescribing for those 
aged 90 or more in both men (OR 3.22, 95%CI 1.74 to 5.95) and women (OR 3.02, 95%CI 1.96 to 4.65) compared to 
those 55-59 years (Table 5). There was higher prescribing of anti-psychotics in those living in the most deprived 
neighbourhoods in men but not women. There were no significant differences by type of neighbourhood. 
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Table 4: Odds ratios of drug treatment for newly recorded depression symptoms in men and women by age, deprivation and type of neighbourhood 
 
  
  
Anti-depressant prescription Anxiolytic or hypnotic prescription 
Men Women Men Women 
OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* 
 
Age group 
55-59 years 
60-64 years 
65-69 years 
70-74 years 
75-79 years 
80-84 years 
85-89 years 
90+ years 
 
 
 
1 
0.92 (0.82, 1.03) 
0.77 (0.67, 0.89) 
0.82 (0.71, 0.95) 
0.97 (0.84, 1.12) 
1.06 (0.9, 1.25) 
1.33 (1.11, 1.6) 
1.23 (0.9, 1.67) 
 
<0.001 
 
 
 
 
1 
0.94 (0.85, 1.03) 
0.86 (0.76, 0.96) 
0.96 (0.85, 1.08) 
0.91 (0.81, 1.01) 
1.03 (0.91, 1.17) 
1.12 (0.96, 1.29) 
1.29 (1.08, 1.55) 
 
<0.001 
 
 
1 
0.97 (0.83, 1.13) 
1.03 (0.86, 1.22) 
1.25 (1.04, 1.49) 
1.17 (0.98, 1.40) 
1.37 (1.14, 1.64) 
1.44 (1.14, 1.82) 
1.35 (0.98, 1.87) 
 
<0.001 
 
 
1 
1.1 (0.98, 1.25) 
1.29 (1.13, 1.48) 
1.28 (1.11, 1.47) 
1.22 (1.07, 1.4) 
1.25 (1.08, 1.45) 
1.28 (1.1, 1.49) 
1.15 (0.95, 1.39) 
 
0.002 
 
Deprivation 
1 (lowest) 
2 
3 
4 
5 (highest) 
 
 
1 
1.13 (0.98, 1.3) 
1.14 (0.95, 1.36) 
1.12 (0.93, 1.36) 
1.28 (1.03, 1.59) 
 
0.20 
 
 
1 
1.09 (0.96, 1.25) 
1.03 (0.90, 1.18) 
1.12 (0.96, 1.31) 
1.18 (1, 1.39) 
 
0.24 
 
 
1 
1.02 (0.86, 1.20) 
0.99 (0.83, 1.17) 
0.91 (0.75, 1.10) 
0.80 (0.64, 1.01) 
 
0.26 
 
 
1 
0.97 (0.85, 1.09) 
0.85 (0.75, 0.98) 
0.94 (0.81, 1.08) 
0.80 (0.67, 0.96) 
 
0.04 
 
Neighbourhood 
Urban 
Town and fringe 
Village, hamlet, 
isolated dwelling 
 
 
1 
0.94 (0.77, 1.14) 
0.91 (0.73, 1.13) 
 
0.63 
 
 
1 
1.0 (0.86, 1.17) 
0.99 (0.82, 1.19) 
 
0.99 
 
 
1 
1.03 (0.87, 1.23) 
1.02 (0.83, 1.24) 
 
0.93 
 
 
1 
1.1 (0.95, 1.27) 
0.95 (0.82, 1.1) 
 
0.25 
* From Wald test for heterogeneity 
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Table 5: Odds ratios of drug treatment and referrals for newly recorded depression symptoms in men and women by age, deprivation and type of neighbourhood 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* From Wald test 
for heterogeneity 
  
  
Antipsychotic prescription Referral for psychological therapies 
Men Women Men Women 
OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* OR (95%CI) p-value* 
 
Age group 
55-59 years 
60-64 years 
65-69 years 
70-74 years 
75-79 years 
80-84 years 
85-89 years 
90+ years 
 
 
 
1 
0.94 (0.61, 1.45) 
1.59 (1.04, 2.42) 
1.49 (0.97, 2.3) 
1.82 (1.24, 2.68) 
2.27 (1.48, 3.46) 
1.94 (1.2, 3.13) 
3.22 (1.74, 5.95) 
 
 
<0.001 
 
 
 
 
 
 
 
 
1 
1.3 (0.91, 1.86) 
1.83 (1.33, 2.52) 
1.42 (0.95, 2.14) 
2.08 (1.41, 3.06) 
1.55 (1, 2.41) 
2.86 (1.92, 4.25) 
3.02 (1.96, 4.65) 
 
 
<0.001 
 
 
 
 
 
 
 
 
1 
0.92 (0.72, 1.18) 
0.51 (0.36, 0.74) 
0.24 (0.15, 0.40) 
0.35 (0.23, 0.52) 
0.16 (0.08, 0.33) 
0.16 (0.07, 0.36) 
0.21 (0.06, 0.67) 
 
 
<0.001 
 
 
 
 
 
 
1 
0.84 (0.67, 1.06) 
0.66 (0.52, 0.84) 
0.36 (0.25, 0.53) 
0.33 (0.23, 0.49) 
0.25 (0.18, 0.36) 
0.17 (0.1, 0.29) 
0.10 (0.04, 0.27) 
 
 
<0.001 
 
 
 
 
 
 
Deprivation 
1 (lowest) 
2 
3 
4 
5 (highest) 
 
 
1 
1.03 (0.68, 1.55) 
1.48 (1.01, 2.16) 
1.75 (1.21, 2.54) 
1.70 (1.12, 2.59) 
 
0.004 
 
 
1 
1.06 (0.79, 1.41) 
1.12 (0.82, 1.53) 
1.21 (0.92, 1.58) 
1.16 (0.83, 1.62) 
 
0.69 
 
 
1 
0.97 (0.66, 1.43) 
1.01 (0.68, 1.50) 
1.01 (0.62, 1.66) 
0.87 (0.52, 1.46) 
 
0.94 
 
 
1 
0.79 (0.57, 1.09) 
0.88 (0.62, 1.26) 
0.92 (0.60, 1.42) 
0.78 (0.49, 1.23) 
 
0.53 
 
Neighbourhood 
Urban 
Town and fringe 
Village, hamlet, 
isolated dwelling 
 
 
1 
0.99 (0.67, 1.45) 
0.63 (0.35, 1.12) 
 
0.28 
 
 
1 
0.84 (0.63, 1.13) 
1.02 (0.72, 1.45) 
 
0.50 
 
 
1 
1.11 (0.66, 1.86) 
0.66 (0.39, 1.10) 
 
0.15 
 
 
1 
1.07 (0.68, 1.68) 
1.03 (0.69, 1.55) 
 
0.96 
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Supplementary Table 1: Treatment initiations and time to treatment for depression diagnoses and 
symptoms  
 
Treatment 
  
Overall   no. 
(%) treatment 
initiations 
Time of treatment initiation in those started on each treatment. N(%) 
0 days 1-14 days 15-30 days 1-6 months 
Depression diagnoses  
(N=20225) 
     
Anti-depressant drugs 17619 (87.1%) 15819 (89.8%) 754 (4.3%) 421 (2.4%) 625 (3.5%) 
Hypnotics 2879 (14.2%) 1002 (34.8%) 579 (20.1%) 467 (16.2%) 831 (28.9%) 
Anxiolytics 1864 (9.2%) 517 (27.7%) 407 (21.8%) 270 (14.5%)  670 (36%) 
Antipsychotics 554 (2.7%) 91 (16.4%) 91 (16.4%) 92 (16.6%) 280 (50.6%) 
Psychological therapies 712 (3.5%) 224 (31.5%) 195 (27.4%) 70 (9.8%) 223 (31.3%) 
 
Depression Symptoms 
(N=27396)   
    
Anti-depressant drugs 16072 (58.7%) 12437 (77.4%) 1495 (9.3%) 711 (4.4%) 1429 (8.9%) 
Hypnotics 3666 (13.4%) 1272 (34.7%) 770 (21.0%) 613 (16.7%) 1011 (27.6%) 
Anxiolytics 2303 (8.4%) 531 (23.1%) 461 (20.0%) 339 (14.7%) 972 (42.2%) 
Antipsychotics 752 (2.7%) 113 (15.0%) 165 (21.9%) 118 (15.7%) 356 (47.4%) 
Psychological therapies 933 (3.4%) 328 (35.2%) 300 (32.1%) 83 (8.9%) 222 (23.8%) 
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Non-pharmacological treatments 
As with those with depression diagnoses, recorded referrals for psychological therapies for older people with 
depression symptoms decreased steadily with increasing age (Table 5). For example, men aged 80-84 had six times 
lower odds of a referral recorded than men aged 55-59 years (OR 0.16, 95%CI 0.08 to 0.33) and women aged 80-84 
years had four times lower odds of a recorded referral than women aged 55-59years (OR 0.25, 95%CI 0.18 to 0.36). 
There were no significant differences in referrals for psychological therapies by either deprivation or type of 
neighbourhood.   
 
Sensitivity analysis  
We explored the impact of differential drop-out by age, as more people left the dataset without six months follow-up 
in the oldest age groups.  This showed that using the best (all people who leave the practice are treated) and worst 
(no people are treated) case scenarios had little impact on the findings for most outcomes, with overlapping 
confidence intervals. The exception was referrals to psychological therapies for those aged 80 or more, where our 
observed findings were close to the worst case scenario (those leaving the practice within six months are not referred), 
and significantly lower than the best case scenario (that all people who leave the practice with depression are referred 
for psychological therapies within six months from the onset of their depression/symptom recording), however this 
scenario is very unlikely in practice. 
 
Discussion 
Treatment rates with anti-depressants are high across all ages for older adults recorded with a new episode of both 
depression diagnoses and symptoms, and with the majority treatment is initiated on the same day as the diagnosis or 
symptom is first recorded. There is little variation in initiation of anti-depressant drugs by age for those with a new 
recorded depression diagnosis – the majority of people are started on an anti-depressant regardless of age, gender, 
deprivation or neighbourhood. A J-shaped variation in treatment with anti-depressants by age is seen, however, for 
those with recorded new symptoms of depression (e.g. ‘low mood’), with lowest prescribing in those 65-69 years and 
higher rates in age 85+ years in both men and women. Prescribing of anxiolytics, hypnotics and antipsychotics all 
increased with increasing age, particularly for anti-psychotics, where prescribing was much higher in the oldest age 
groups.  Overall recorded referrals for psychological therapies including counselling were low, and steadily decreased 
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with increasing age, for those with both new recorded episodes of depression diagnoses and symptoms, and those in 
the older age groups (e.g. 80 years or more) were much less likely to have a recorded referral. 
 
Treatment rates with anti-depressants for older people in our study are much higher than previous research on 
primary care prescribing (Harman et al., 2006) and the fact that treatment was commonly initiated on the same day 
the depression diagnosis was first entered, suggests that formal coding for depression diagnoses in GP records may 
be driven in part by decisions to prescribe anti-depressants. It was also striking that anti-depressant treatment rates, 
while lower than for depression diagnoses, are still high for those coded with symptoms only (e.g. ‘low mood’), 
suggesting that GPs are either opting to use less specific codes for people they feel have significant depression, or that 
they are prescribing anti-depressants for people with milder symptoms who may not meet criteria for a major 
depressive episode. Anti-depressant prescribing for this potentially milder group with a recorded depression symptom 
increases in the oldest age groups (e.g. 85+ years), despite some evidence suggesting that in older people efficacy of 
anti-depressants declines with increasing age, and with lower severity (Calati et al., 2013). Most trials of the 
effectiveness of anti-depressants in older people have been conducted with a ‘younger old’ population, with a mean 
age of around 71 years, and thus our knowledge of efficacy for the oldest age groups is limited (Benraad et al., 2016).  
The different patterns of prescribing with age for those with depression diagnoses and symptoms suggests that where 
symptoms are severe enough to record a depression diagnosis GPs prescribe anti-depressants regardless of age, but 
for potentially milder episodes recorded only as symptoms of low mood, age, and contextual factors related to age 
(e.g. employment, or frailty with increasing age) may influence decisions to prescribe. 
 
Our findings are also consistent with other work demonstrating that prescribing of hypnotics increases with increasing 
age (Olfson et al., 2015) and anti-psychotic prescribing in people without documented severe mental illness is high 
and rises with age (Marston et al., 2014). We did not exclude those with co-morbid psychosis, and so some prescribing 
may be appropriate for this indication. Some of this might be explained by prescribing of anti-psychotics for co-morbid 
conditions such agitation in dementia, however due to the risk of adverse side effects such as stroke in older people 
(Douglas & Smeeth, 2008) anti-psychotic prescribing is rarely indicated for this group. Similarly hypnotics have been 
associated with increased risk of adverse effects including cognitive impairment (Tannenbaum et al., 2012), fractures 
(Xing et al., 2014) and death (Parsaik et al., 2016) and so continued increased use in this older age group is concerning. 
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The decline in referrals for psychological therapies including counselling with increasing age is consistent with other 
evidence, which has demonstrated low treatment rates in older age groups (Unützer et al., 2000; Crystal et al., 2003; 
Harman et al., 2004; Kessler et al., 2005; de Lusignan et al., 2012), and low self-reported use of psychological therapies 
in older people in the general population in the recent Adult Psychiatric Morbidity Survey in England (Lubian et al., 
2016). This is despite evidence suggesting that CBT has similar effectiveness in later life (Gould et al., 2012), and that 
once in therapy older people have high levels of adherence (Serfaty et al., 2009). Our study demonstrated a particularly 
steep decline in recorded referrals for psychological therapies with increasing age, suggesting that some of the low 
self-reported use of psychological therapies by older people is explained by low referrals from their GP. 
 
This is the first study to our knowledge to explore variations in primary care treatment for new depression 
diagnoses/depression symptoms by age across all modalities, in a large nationally representative dataset. There are 
several potential limitations with this work. Depression is under-recognised at all ages in primary care settings, with a 
sensitivity of 50% for unassisted diagnoses of depression by GPs (Mitchell et al., 2009). This may be slightly worse for 
older age groups (Mitchell et al., 2010). Our analysis therefore only represents the treatment for those with diagnoses 
and symptoms recorded in their medical records, and is therefore not generalizable to all depression in the community, 
including those who may benefit from treatment but are not or mis-diagnosed. The accuracy of GP recorded 
depression diagnoses is higher, with a specificity of 81% against diagnostic instruments (Mitchell et al., 2009).  We do 
not know the accuracy or validity of GP recorded depression symptoms. We defined new episodes of depression as 
having no entry for any depression diagnosis or symptom codes or prescriptions for anti-depressant treatment in the 
previous 12 months. GPs do not consistently enter data on when a patient has recovered from their depression, and 
it is possible that some people may have continuing depression while having no recorded contact with their GP for 
this problem. However the majority (97.4%) only had a single recorded episode during follow-up, so this is unlikely to 
have affected our findings.   
 
Common to all studies on primary care data, there will be some missing data. Prescription data are well recorded 
(Bourke et al., 2004; Lewis et al., 2007), and the psychotropic drugs of interest are not available without a prescription. 
These data represent a record of medicines issued, and the patient may not be taking the medication as prescribed, 
however it does represent the doctor’s treatment strategy, our key measurement of interest. There were low recorded 
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rates of referrals for psychological therapies in comparison to evidence from other countries such as the USA (Harman 
et al., 2006), however our data is consistent with other UK data from local pilot sites of the Increasing Access to 
Psychological Therapies (IAPT) programme (de Lusignan et al., 2012).  Nonetheless recorded referrals are likely to 
reflect an under-recording of true rates, as not all referrals will be formally coded on GP systems. GP records would 
not include self-referrals to psychological therapies, though as evidence suggests that uptake of IAPT services is low in 
older people (Royal College of Psychiatrists, 2013), this is unlikely to explain the lower recorded GP referral rates. We 
do not know whether any such under-recording systematically varies by age, so our results may be consistent with, 
under or over-estimated the true differences. There were fewer people in our sample in the oldest age category of 90 
years or more (340 people with new recorded depression and 964 people with new symptoms), affecting the precision 
of our estimates for this group. A small proportion of people had less than six months of follow-up data due to death 
(2% of those with depression diagnoses, 3.6% of those with symptoms) or leaving the practice (2% of those with 
depression diagnoses, 2.5% if those with symptoms), however this attrition was higher in the oldest age groups.  Our 
sensitivity analysis suggested that this is unlikely to have had a significant impact on our results.  
 
Our findings suggest that there are opportunities to improve how GPs in the UK may treat depression in older adults.  
Hypnotics/anxiolytics and anti-psychotics appear to be over-utilised and prescribing rates rise with increasing age.  
Recording of referrals for psychological therapies was low and decreased substantially with increasing age.  The 
differences in choice of therapy in older adults across all ages are stark; for depression 87% are prescribed anti-
depressants, and only 3.5% referred to psychological therapies within six months.  This is despite evidence of the 
benefit of psychological therapies in older people with a lower NNT (3 vs. 6.7 for antidepressants). There was no 
evidence that GPs were more reluctant to initiate anti-depressants in the oldest age groups with more complex co-
morbidities; prescribing of anti-depressants was slightly higher in the oldest age groups for those with new 
depression symptoms. The prevalence of co-morbidities, frailty and disability increase greatly in the very old (Collard 
et al., 2012), and that this may limit accessibility of psychological therapies, which may be driving the reduced 
referrals and compensatory increases in drug prescribing in depression. In addition this age group has a lower use of 
information technology, limiting access to low intensity computer-based psychological therapies that are now widely 
available for milder depression.   GPs may therefore use anti-depressants and other drugs more often due to a 
perceived or real lack of alternative options to manage low mood in the oldest age groups.  Other possible 
22 
 
explanations for lower referrals to psychological therapies may include the prioritisation of physical over mental 
health needs  (Murray et al 2006) and a view that feeling low is a natural consequence of ageing and loneliness that 
does not need treatment (Murray et al., 2006; Corcoran et al., 2013).  These would not however explain the high 
rates of anti-depressant prescribing in older age groups. Commissioners should consider how they can ensure that 
those with low mood in this group have access to non-drug treatment.  Further research should understand why 
older people are referred less often for psychological therapies, and evaluate the cost-effectiveness of alternatives 
for psychological support of the oldest age groups. 
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